ADVM Quote, Financials, Valuation and Earnings

Eli Lilly & Co. has a net margin of -2713.4% compared to Adverum Biotechnologies, Inc.'s net margin of 31.72%. Adverum Biotechnologies, Inc.'s return on equity of -558.69% beat Eli Lilly & Co.'s return on equity of 106.26%.

Adverum Biotechnologies, Inc. has a consensus price target of $4.90, signalling upside risk potential of 17.51%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,045.59 which suggests that it could grow by 1.16%. Given that Adverum Biotechnologies, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Adverum Biotechnologies, Inc. is more attractive than Eli Lilly & Co..

Adverum Biotechnologies, Inc. has a beta of 0.869, which suggesting that the stock is 13.055% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Adverum Biotechnologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.58% to investors and pays a quarterly dividend of $1.50 per share. Adverum Biotechnologies, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Adverum Biotechnologies, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Adverum Biotechnologies, Inc.'s net income of -$47.7M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Adverum Biotechnologies, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 51.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adverum Biotechnologies, Inc. is 89.16x versus 15.86x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -2713.4% compared to Adverum Biotechnologies, Inc.'s net margin of 21.32%. Adverum Biotechnologies, Inc.'s return on equity of -558.69% beat Pfizer Inc.'s return on equity of 10.84%.

Adverum Biotechnologies, Inc. has a consensus price target of $4.90, signalling upside risk potential of 17.51%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13.57%. Given that Adverum Biotechnologies, Inc. has higher upside potential than Pfizer Inc., analysts believe Adverum Biotechnologies, Inc. is more attractive than Pfizer Inc..

Adverum Biotechnologies, Inc. has a beta of 0.869, which suggesting that the stock is 13.055% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Adverum Biotechnologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.73% to investors and pays a quarterly dividend of $0.43 per share. Adverum Biotechnologies, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Adverum Biotechnologies, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Adverum Biotechnologies, Inc.'s net income of -$47.7M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Adverum Biotechnologies, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adverum Biotechnologies, Inc. is 89.16x versus 2.32x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals, Inc. has a net margin of -2713.4% compared to Adverum Biotechnologies, Inc.'s net margin of -3135.32%. Adverum Biotechnologies, Inc.'s return on equity of -558.69% beat Recursion Pharmaceuticals, Inc.'s return on equity of -80.23%.

Adverum Biotechnologies, Inc. has a consensus price target of $4.90, signalling upside risk potential of 17.51%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $6.33 which suggests that it could grow by 35.91%. Given that Recursion Pharmaceuticals, Inc. has higher upside potential than Adverum Biotechnologies, Inc., analysts believe Recursion Pharmaceuticals, Inc. is more attractive than Adverum Biotechnologies, Inc..

Adverum Biotechnologies, Inc. has a beta of 0.869, which suggesting that the stock is 13.055% less volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Adverum Biotechnologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adverum Biotechnologies, Inc. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Adverum Biotechnologies, Inc. quarterly revenues are --, which are smaller than Recursion Pharmaceuticals, Inc. quarterly revenues of $5.2M. Adverum Biotechnologies, Inc.'s net income of -$47.7M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$162.3M. Notably, Adverum Biotechnologies, Inc.'s price-to-earnings ratio is -- while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adverum Biotechnologies, Inc. is 89.16x versus 42.75x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

X4 Pharmaceuticals, Inc. has a net margin of -2713.4% compared to Adverum Biotechnologies, Inc.'s net margin of -1689.24%. Adverum Biotechnologies, Inc.'s return on equity of -558.69% beat X4 Pharmaceuticals, Inc.'s return on equity of -279.19%.

Adverum Biotechnologies, Inc. has a consensus price target of $4.90, signalling upside risk potential of 17.51%. On the other hand X4 Pharmaceuticals, Inc. has an analysts' consensus of $7.38 which suggests that it could grow by 126.92%. Given that X4 Pharmaceuticals, Inc. has higher upside potential than Adverum Biotechnologies, Inc., analysts believe X4 Pharmaceuticals, Inc. is more attractive than Adverum Biotechnologies, Inc..

Adverum Biotechnologies, Inc. has a beta of 0.869, which suggesting that the stock is 13.055% less volatile than S&P 500. In comparison X4 Pharmaceuticals, Inc. has a beta of 0.421, suggesting its less volatile than the S&P 500 by 57.861%.

Adverum Biotechnologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. X4 Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adverum Biotechnologies, Inc. pays -- of its earnings as a dividend. X4 Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Adverum Biotechnologies, Inc. quarterly revenues are --, which are smaller than X4 Pharmaceuticals, Inc. quarterly revenues of $1.8M. Adverum Biotechnologies, Inc.'s net income of -$47.7M is lower than X4 Pharmaceuticals, Inc.'s net income of -$29.8M. Notably, Adverum Biotechnologies, Inc.'s price-to-earnings ratio is -- while X4 Pharmaceuticals, Inc.'s PE ratio is 0.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adverum Biotechnologies, Inc. is 89.16x versus 1.54x for X4 Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.